Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Portfolio Pulse from
Connect Biopharma (CNTB) received a Nasdaq deficiency notice for its stock price falling below the $1.00 minimum requirement. The company has 180 days (until September 22, 2025) to regain compliance, with potential for an additional 180-day extension if certain conditions are met. Failure to comply could result in delisting.
March 28, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Company must raise stock price above $1.00 by September 22, 2025, or risk being removed from Nasdaq Global Market. Potential actions include stock reverse split or raising capital.
Nasdaq deficiency notice signals significant stock price challenges, which could negatively impact investor sentiment and stock performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
Nasdaq demonstrates commitment to maintaining listing quality standards by issuing compliance notice to Connect Biopharma.
Routine enforcement of listing rules with minimal direct financial impact on Nasdaq itself.
CONFIDENCE 70
IMPORTANCE 20
RELEVANCE 30